HAVING DISCUSSED IMPORTANT lymphoma and chronic lymphocytic leukemia abstracts from the 66th American Society of Hematology ...

SGX301 has shown rapid and sustained benefit in early cutaneous T-cell lymphoma in an investigator-initiated study, with good ...

Fengting Yan, MD, PhD, discusses how her clinical practice is informed by data and guidelines available on testing in breast cancer.

Following a recent Type D meeting with the FDA, a phase 3 clinical trial design for darovasertib in primary uveal melanoma ...

Panelists discuss how KEYNOTE-799 provides updated data on safety, toxicity, positive response rates, and median survival rates for both squamous and nonsquamous non–small cell lung cancer treatments.

In a live virtual event, Thomas C. Krivak, MD, reviewed the key studies of PARP inhibitor and bevacizumab maintenance in ...

The Oncology Brothers provide a comprehensive recap of the key highlights presented at the European Lung Cancer Conference (ELCC 2025) along with their expert final thoughts and clinical ...

Panelists discuss how response rates, progression-free survival, and overall survival data presented at the European Lung Cancer Conference (ELCC 2025) demonstrate meaningful clinical outcomes while ...

Enriqueta Felip, MD, PhD, discusses the design of the phase 3 3475A-D77 trial evaluating subcutaneous pembrolizumab in metastatic NSCLC.

Panelists discuss how the practice-changing LAURA study demonstrates the critical importance of next-generation sequencing in guiding therapeutic decisions for non–small cell lung cancer (NSCLC) ...

Panelists discuss how the MARIPOSA study design demonstrates an overall survival benefit while effectively preventing adverse events in patients.

A panelist discusses how identifying steroid-dependent or steroid-refractory (SR) graft-vs-host disease (GVHD) requires careful clinical monitoring, with the determination typically made when patients ...